Evidence that fodipir (DPDP) binds neurotoxic Pt\(^{2+}\) with a high affinity: An electron paramagnetic resonance study

Jan Eric Stehr\(^{2}\)*, Ingemar Lundström\(^{1}\) & Jan Olof G. Karlsson\(^{2}\)*

Oxaliplatin typically causes acute neuropathic problems, which may, in a dose-dependent manner, develop into a chronic form of chemotherapy-induced peripheral neuropathy (CIPN), which is associated with retention of Pt\(^{2+}\) in the dorsal root ganglion. A clinical study by Coriat and co-workers suggests that co-treatment with mangafodipir [Manganese(II) DiPyridoxyl DiPhosphate; MnDPDP] cures ongoing CIPN. These authors anticipated that it is the manganese superoxide dismutase mimetic activity of MnDPDP that explains its curative activity. However, this is questionable from a pharmacokinetic perspective. Another, but until recently undisclosed possibility is that Pt\(^{2+}\) outcompetes Mn\(^{2+}\)/Ca\(^{2+}\)/Zn\(^{2+}\) for binding to DPDP or its dephosphorylated metabolite PLED (diPyridoxyl EthylDiamine) and transforms toxic Pt\(^{2+}\) into a non-toxic complex, which can be readily excreted from the body. We have used electron paramagnetic resonance guided competition experiments between MnDPDP \((\log K_{ML} \approx 15)\) and K\(_{2}\)PtCl\(_4\), and between MnDPDP and ZnCl\(_2\) \((\log K_{ML} \approx 19)\), respectively, in order to obtain an estimate the \(\log K_{ML}\) of PtDPDP. Optical absorption spectroscopy revealed a unique absorption line at 255 nm for PtDPDP. The experimental data suggest that PtDPDP has a higher formation constant than that of ZnDPDP, i.e., higher than 19. The present results suggest that DPDP/PLED has a high enough affinity for Pt\(^{2+}\) acting as an efficacious drug in chronic Pt\(^{2+}\)-associated CIPN.

Oxaliplatin-associated chemotherapy-induced peripheral neuropathy (CIPN) is the most frequent cause of complete discontinuation of an otherwise successful chemotherapy in colorectal cancer (CRC) patients. Chronic CIPN is characterized by bilaterally symmetrical sensory symptoms, e.g., numbness, tingling, and pain appearing in the feet and hands. At present there is no approved therapy for CIPN. The exact mechanism behind oxaliplatin-associated CIPN is poorly understood but it is associated to retention of Pt\(^{2+}\) in the dorsal root ganglion (DRG) and subsequent binding to proteins, resulting in increase in cellular oxidative and nitrosative stress\(^1\). Mangafodipir (Manganese(II) DiPyridoxyl DiPhosphate; MnDPDP), after being metabolized into cell-permeable Manganese(II) Pyridoxyl EthylDiamine (MnPLED), presumably attacks cellular oxidative and nitrosative stress at three levels\(^2\): (i) it lowers the intracellular level of O\(_2^*\) directly through its manganese superoxide dismutase (MnSOD)-mimetic activity; (ii) it binds and disarms endogenous transition metals, particularly Fe\(^{2+}/Fe^{3+}\) and Cu\(^{+}/Cu^{2+}\), and thus arrests incorporation of \(\cdot\)NO into tyrosine 34 and a subsequent irreversible inactivation of the mitochondrial MnSOD and production of highly toxic OH\(^*\) radicals; and (iii) it replaces the irreversible inactivated MnSOD. By these properties, MnDPDP effectively switches off the vicious circle that eventually may cause severe tissue damage\(^3\).

In its catalytic activity complexed Mn\(^{2+}\) of the MnSOD mimic is first oxidized by O\(_2^*\) to Mn\(^{3+}\). Subsequently, the formed Mn\(^{3+}\) is reduced to Mn\(^{2+}\) by a second O\(_2^*\), making the reaction a true metal-catalyzed dismutation like that catalyzed by the SOD enzymes. Free Mn\(^{3+}\) ions in non-complexing buffers, by contrast, are poorly reactive\(^1\) with O\(_2^*\).

Recent publications by Coriat and coworkers\(^4\), Glimelius et al.\(^5\), and a prior case report by Yri et al.\(^6\) describe that co-treatment with intravenously administered MnDPDP or Ca\(_4\)Mn(DPDP)\(_2\) (tetraCalcium monoManganese(II) penta(DiPyridoxyl DiPhosphate) (Fig. 1) may reduce oxaliplatin-associated CIPN in CRC patients.

\(^1\)Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden. \(^2\)Division of Drug Research/Pharmacology, Linköping University, Linköping, Sweden. *email: jan.eric.stehr@liu.se; janolof.karlsson@ktias.com
Importantly, the data from the Coriat et al. study suggest that MnDPDP not only prevents but surprisingly also cures chronic CIPN. This particular study showed that patients with pre-existing oxaliplatin-associated CIPN (grade 2 or worse on a 1–3 scale) improved after combined oxaliplatin and MnDPDP treatment. Because the severity of oxaliplatin-associated CIPN correlates with the cumulative dose, continued treatment with oxaliplatin alone is expected to aggravate CIPN. Combined treatment is hence in the best case expected to prevent further aggravation. However, the above cited publications take for granted that it is the MnSOD-mimetic activity of MnDPDP, as described by Asplund et al., Brurok et al. and Bedda et al., that explains its therapeutic activity against chronic oxaliplatin-associated CIPN. Id est, in a similar manner as it protects against myocardial injuries caused by ischemia-reperfusion and doxorubicin-induced cardiotoxicity, chemotherapy-induced myelosuppression and paracetamol (acetaminophen)-induced liver failure, respectively.

The in vivo protection of MnDPDP or Ca₄Mn(DPDP)₅ against oxaliplatin-induced myelosuppression in mice takes place without interfering negatively with the tumoricidal activity of oxaliplatin. Contrary, these studies showed that both MnDPDP and Ca₄Mn(DPDP) increased the tumoricidal activity of oxaliplatin. In vitro studies suggest that the increased tumoricidal activity of MnDPDP and Ca₄Mn(DPDP) is an inherent property of DPDP/CaDPDP alone and not of the intact Mn²⁺ complex. Glimelius et al. reported that Ca₄Mn(DPDP) did not interfere negatively with oxaliplatin-containing chemotherapies in colorectal cancer patients.

An externally administered MnSOD mimetic is expected to result in only a transient increase in MnSOD mimetic activity; mainly governed by the elimination of the MnPLED-derivatives from the body (i.e., MnDPD, MnDPMP (Manganese(II) DiPyridoxyl MonoPhosphate) and MnPLED). Pharmacokinetic data from human volunteers, as reported by Toft et al., show that very little or no DPDP/DPMP/PLED-bound Mn²⁺ is detected in the blood plasma 2 hours after administration of MnDPDP, whereas ZnPLED is still detected 12 hours after administration. On theoretical grounds a MnPLED-derivative is hence expected to have a preventive efficacy when administered close to the oxaliplatin administration and not a curative efficacy on an already established CIPN. The therapeutic window of MnDPDP and its metabolite MnPLED is likely too short for having any major effect on an already established chronic CIPN, through its MnSOD-mimetic activity. The situation is quite different when it comes to acute and transient increase in reactive oxygen species (ROS) and reactive nitrogen species (RNS) - such as those seen in situations of ischemia-reperfusion injuries, acetaminophen-induced liver failure, chemotherapy-induced myelosuppression, doxorubicin-induced cardiotoxicity, and acute CIPN, where there is little or no doubt that the therapeutic effects are mainly due to the MnSOD-mimetic activity of MnDPDP/Ca₄Mn(DPDP)₅.

When it comes to oxidative and nitrosative stress caused by oxaliplatin-associated Pt²⁺, another but until recently undisclosed possibility is that Pt²⁺ outcompetes Mn²⁺ for binding to DPDP (or its metabolites DPMP and PLED) and transforms toxic Pt²⁺ into a non-toxic complex which, like other metal-DPDP/DPMP/PLED complexes, can be readily excreted through the kidneys. Cu²⁺ binds with high affinity to DPDP and PLED, with a formation constant (10²⁸ logKₛₐₚ) about 22 for both compounds. Cu²⁺ binds with four coordinates in a square pyramidal geometry and has an ionic radius of 75 pm. Similarities between Pt²⁺ and Cu²⁺ with respect to binding geometry and ionic radius of 60 pm, suggest that Pt²⁺ should bind to DPDP/PLED with high affinity. The corresponding affinity of Mn²⁺ for DPDP is approximately seven orders of magnitude lower than that of Cu²⁺.

It is, however, not an easy task to determine the affinity of Pt²⁺ for hexa-dentate chelators, which is reflected by the apparent absence of formation constants of Pt²⁺ for common hexa-dentate chelators, such as EDTA, in the literature. The main reason is most probably a lack of true water-soluble Pt²⁺ salts in addition to slow Pt²⁺ exchange kinetics. K₂PtCl₄ is a water soluble compound, which dissolves into two K⁺ cations and a square planar metal complex of Pt(II)Cl₄. This compound is an important starting material for preparation of other coordination complexes of Pt²⁺ aimed for e.g., medical use. Although the chloride ligands of [PtCl₄]²⁻ are displaced by many other ligands, the ligand-exchange behavior of Pt(II)complexes is quite slow, which gives them a high kinetic stability and results in ligand-exchange reactions of minutes to days, rather than microseconds to seconds for many other coordination compounds.
In the present paper we have used the difference in electron paramagnetic resonance (EPR) spectra of MnDPDP and hexaqua-Mn$^{2+}$ to measure release of Mn$^{2+}$ from DPDP (Fig. 2), as described by Schmidt and co-workers\(^\text{21}\), in exchange for Pt$^{2+}$ and Zn$^{2+}$.

**Results**

**EPR-guided competition experiments.** EPR-guided competition experiments between MnDPDP and ZnCl$_2$ or K$_2$PtCl$_4$ are presented in Fig. 3. The resulting competition curve for 100µM MnDPDP and 10–1000µM ZnCl$_2$ is more or less identical to that presented by Schmidt and co-workers\(^\text{21}\). The corresponding curve for 100µM MnDPDP and 10–1000µM K$_2$PtCl$_4$ lies to the left of the former. The pD$_2$ [−10\log of the concentrations (M) of a drug causing half maximal responses; EC$_{50}$] (together with 95% confidence interval) values for K$_2$PtCl$_4$ and ZnCl$_2$ were 4.280 (4.227–4.332) and 4.173 (4.127–4.218), respectively, i.e., there is a statistically significant difference between these two pD$_2$ values. This suggests that Pt$^{2+}$ in fact has a higher affinity than Zn$^{2+}$ for DPDP.

The present curve for Zn$^{2+}$ and that of Schmidt et al. are close to 100% exchange for all concentrations of ZnCl$_2$. That means that the stability constant of Pt$^{2+}$ may be substantially higher than that for Zn$^{2+}$. The E$_\text{max}$ (maximal response) for the K$_2$PtCl$_4$ and ZnCl$_2$ were 95.62µM (89.54–101.7) and 101.2µM (95.18–111.2), respectively. There was a clear tendency, although not statistically significant, that the K$_2$PtCl$_4$ curve did not reach full metal exchange (100µM). The K$_2$PtCl$_4$ + MnDPDP samples got a weak yellow-brownish color during incubation. This was not seen in the MnDPDP control sample or in the ZnCl$_2$ + MnDPDP samples, which may suggest that Pt$^{2+}$-driven oxidation of Mn$^{2+}$ had occurred to some extent in the K$_2$PtCl$_4$ + MnDPDP samples, which in turn may explain the somewhat lower E$_\text{max}$ than the expected.

---

**Figure 2.** EPR standard curve for free Mn$^{2+}$. The double integral of the EPR signal (insert) in arbitrary units is plotted against the concentration of MnCl$_2$.

**Figure 3.** Metal exchange of MnDPDP by Zn$^{2+}$ and Pt$^{2+}$. The invisibility of MnDPDP at room temperature due to its high ZFS was used to monitor exchange of Mn$^{2+}$ for Zn$^{2+}$ and Pt$^{2+}$, respectively\(^\text{21}\).
Optical absorption spectroscopy. Optical absorption measurements on pure MnDPDP with a 100 µM concentration in aqueous solution show roughly the same UV-absorption maxima at 220, 257 and 319 nm as reported by Tirkkonen et al.22. 100 µM MnCl₂ in aqueous solution does not exhibit any peaks in the measured spectral range. The optical absorption measurements in aqueous solutions of 100 µM K₂PtCl₄ (1), 100 µM DPDP (2), the sum of spectra of K₂PtCl₄ and DPDP (3), 100 µM K₂PtCl₄ + 100 µM DPDP (4) after incubation for 6 h at 60 °C, are depicted in Fig. 4a,b. A comparison between the sum of the individual optical absorption spectra of 100 µM K₂PtCl₄ and 100 µM DPDP (3) and the spectrum of 100 µM K₂PtCl₄ + 100 µM DPDP (4) indicates that Pt²⁺ was bound to DPDP, since the spectrum after incubation differs from the sum of the spectra of the two particular substances. The main difference is that the UV-absorption maximum at 255 nm increases substantially (2.5 times) after incubation. This indicates that the UV-absorption maximum at 255 nm is most likely related to the metal ion bound to DPDP. Qualitatively the spectra of 100 µM K₂PtCl₄ + 100 µM DPDP (4) and 100 µM K₂PtCl₄ + 100 µM MnDPDP (5), after incubation for 6 h at 60 °C, are rather similar, while they both differ significantly from the 100 µM MnDPDP spectrum (6). Firstly, the main UV-absorption maximum in PtDPDP (located at 207 nm) has blue-shifted compared to the 220 nm in MnDPDP. Secondly, the maximum at 319 nm in MnDPDP has been replaced by two peaks located at 296 and 330 nm. These results indicate that in the competition experiments between K₂PtCl₄ + MnDPDP almost all of the Mn²⁺ was replaced by Pt, which confirms the EPR results. The additional weak feature at 380 nm in 100 µM K₂PtCl₄ + 100 µM MnDPDP (5) is related to MnO₂. Other manganese oxides were probably formed as well and added most likely a weak and broad background signal which makes all the peaks appear broadened. This also indicates that Mn²⁺ in DPDP was replaced by Pt²⁺.

Discussion

Oxaliplatin, a third-generation platinum agent, is considered one of the two most important new drugs used in the treatment of CRC.25 Despite the clinical impact and enthusiasm for this agent, the applicability of oxaliplatin is limited, in a large part, by CIPN and myelosuppression. Importantly, chronic neurotoxicity, and not tumor progression, is the most frequent reason that forces patients to forego further therapy with this agent. Because the
approved use of oxaliplatin has, for the first time in over 50 years, improved overall survival in patients with CRC, innovative research with respect to oxaliplatin-induced CIPN is highly appreciated. Clinical data indicate an apparent lack of correlation between Pt\(^{2+}\)-induced neurotoxicity and tumor response, suggesting that neurotoxicity and other adverse events may be prevented without altering tumoricidal efficacy. Furthermore, after administration into patients, oxaliplatin (diaminocyclohexane platinum oxalate) is rapidly metabolized (plasma half-life less than 30 minutes) into numerous metabolites and less than 3% of it is excreted through the kidneys. After sequential replacement of the chlorides with water is a key step in forming a complex with the DNA.

The recent finding by Coriat et al. that MnDPDP has a curative effect on chronic oxaliplatin-associated CIPN through its MnSOD-mimetic activity is from a pharmacokinetic perspective questionable. An until recently undisclosed possibility is that Pt\(^{2+}\) through its MnSOD-mimetic activity is not expected to have any major curative effect. The various therapeutic activities of MnPLED-derivatives and the meaning of them during acute increase in oxidative/nitrosative stress, respectively, are schematically illustrated in Fig. 5. The two therapeutic mechanisms of MnDPDP and Ca\(_4\)Mn(DPDP), i.e., MnSOD mimetic activity and metal chelation activity of DPDP/CaDPDP, and the meaning of them during acute increase in oxidative/nitrosative stress and that caused by a prolonged increase in oxidative/nitrosative stress, such as from retention of Pt\(^{2+}\) in the body. During the acute increase in the cellular stress, MnSOD mimetic activity is the most important mechanism to balance the cellular stress burden, although metal chelation also plays an important role. Pharmacokinetic behavior of MnDPDP in healthy volunteers suggests that the MnSOD mimetic activity of MnDPDP lasts no longer than 2 hours post-injection, whereas the chelation activity lasts about 12 hours. During prolonged increase in cellular stress, causing irreversible inactivation of endogenous mitochondrial MnSOD (the most important endogenous cellular defensive against increased oxidative/nitrosative stress), metal chelation is probably the main mechanism to balance the burden, such as that caused by retention of the transitional metal Pt\(^{2+}\), where chelation of Pt\(^{2+}\) may be of a particularly importance.
renal toxicity without affecting antitumor activity significantly. The sulfur compound (diethyldithiocarbamate; DDTC) was tested in a randomized placebo-controlled trial in 221 patients receiving cisplatin (100 mg/m²) combined with cyclophosphamide or etoposide. DDTC did not reduce the incidence of peripheral neurotoxicity. On the other hand, renal toxicity and treatment withdrawal due to toxicity was significantly higher in the DDTC group than in the control group, presumably illustrating the problem of finding or creating an ideal chelator.

To the best of our knowledge, oxaliplatin with a completely different pharmacokinetic profile in comparison to cisplatin has never been subject for chelation therapy in order to treat oxaliplatin-associated adverse events.

The pharmacokinetics of Pt²⁺-metabolites of oxaliplatin in plasma is typically triphasic in man, characterized by a short initial distribution phase and a long terminal elimination phase with a half-life of about 11 days. Anticipating that 5 half-lives are needed to reach the zero plasma level of Pt²⁺, it will take around 55 days to get all Pt²⁺ out of the body. Curative treatment in CRC patients with oxaliplatin (in combination with 5-fluorouracil) following the FOLFOX regime typically include 12 cycles every 14 days. The pharmacokinetics clearly suggest an increasing burden of Pt²⁺ over the whole treatment period. The long terminal half-life probably represents a slow release of low molecular weight platinum-amino acid conjugates after degradation of cellular macromolecules. It seems plausible that Pt²⁺-elimation during the long elimination phase by having a high enough affinity for Pt²⁺ over the whole treatment period. Such a process may explain the apparent curative effect of MnDPDP on oxaliplatin-associated CIPN. This effect is expected to be amplified in the case of Ca₄Mn(DPDP)₂ (calmangafodipir) due to its 4 time higher content of DPDP at equimolar concentrations of Mn²⁺ (see below and Fig. 1), where Ca³⁺ has about 10,000 time lower affinity for DPDP than Mn²⁺.

Both essential and nonessential metals may exert toxic effects if the dose of exposure exceeds certain levels. Manganese is essential in a number of enzymes, of which MnSOD is of particular relevance, since it protects mitochondria from toxic oxidants. Overexposure to manganese may give rise to “manganism” with Parkinson-like symptoms. Mn²⁺ bound to DPDP is likely non-neurotoxic, but Mn²⁺ released from DPDP may pass the blood-brain-barrier and accumulate in the brain, causing severe neurotoxicity. About 80% of the Mn²⁺ content of MnDPDP is released upon intravenous injection of a clinically relevant dose. It is possible to stabilize MnDPDP by replacing 4/5 of its Mn²⁺ content with Ca²⁺, resulting in a compound known as calmangafodipir [Ca₄Mn(DPDP)₂] [12,13]. At equivalent intravenous Mn²⁺ doses, Ca₄Mn(DPDP)₂ causes considerably less Mn²⁺ release and retention in the rat brain and is significantly more efficacious than MnDPDP to protect mice against oxaliplatin-induced leukocytopenia. Although brain retention of manganese is reduced by about 40%, it still occurs and restricts the use of Ca₄Mn(DPDP)₂. Standard chemotherapy with 5-fluorouracil plus oxaliplatin (FOLFOX) in stage III CRC patients involves 12 consecutive cycles, although the number of cycles may be reduced down to 6 in low-risk stage III CRC patients. From a risk-benefit perspective it seems reasonable to include co-administration of 5 µmol/kg Ca₄Mn(DPDP)₂ in each of these cycles, in order to lower the incidence of acute CIPN and other dose limiting toxicity, such as severe leukocytopenia and mucositis. For more frequent use of Ca₄Mn(DPDP)₂, accumulated Mn²⁺ neurotoxicity will most probably represent an insurmountable obstacle. With regards to Pt²⁺-associated chronic CIPN, the possibility of using “naked” DPDP or Ca₂DPDP may offer a considerable improvement to treat this serious condition. Furthermore, use of non-Mn²⁺ containing DPDP (or its dephosphorylated counterpart PLED), in addition, offers an attractive possibility to treat oxaliplatin-associated chronic CIPN temporarily separated from oxaliplatin administration. Such an approach will enable repeated administration of the chelator over days or weeks in order to transport as much Pt²⁺ as possible away from the body.

MnDPDP has been used as an MRI contrast agent in more than 100,000 patients and repeated dosing of Ca₄Mn(DPDP)₂ has been tested in about 100 patients as an adjunct to chemotherapy, both compounds have been well tolerated. Taking into consideration that it is the toxicity of manganese that limits the use of these compounds, it should be possible to proceed directly to a study with a limited number of patients with chronic oxaliplatin-associated CIPN and test manganese-free DPDP or Ca₂DPDP in a manner similar to that described by Coriat et al., i.e., in patients with severe CIPN (grade ≥ 2 on a 3 graded scale). The extremely high sensitivity and precision of inductively coupled plasma mass spectrometry (ICP-MS) will allow analyses of Pt²⁺ in the urine after administration of DPDP or placebo in patients with chronic oxaliplatin-associated CIPN. Preclinical studies demonstrate that MnPLED-derivative has a tumoricidal activity of its own. Furthermore, the
tumoricidal activity of MnPLED-derivatives seems to be a property of the chelator alone and not a property of the intact Mn(II)complex11,14, which in fact may contribute to increase survival among the CRC patients.

Conclusion
In conclusion, the present study shows that Pt2+ has an affinity for DPDP statistically significantly higher than that for Zn2+. ZnPLED is the main metabolite found in the urine after administration of DPDP, CaDPDP or MnDPDP15 suggesting that DPDP or its metabolites DPMP and PLED may form stable enough metal complexes for fulfilling the above-mentioned criteria. This together with rather rapid excretion kinetics of metal(II)DPDP16, PLED18 and low toxicity, speaks in favour of using DPDP or CaDPDP as a chelation therapeutic drug in conditions of chronic Pt2+ intoxication (Fig. 5), such as that seen after chemotherapy with oxaliplatin and cisplatin.

Methods
Chemicals and reagents. Mangafodipir trisodium (MnDPDP) and fodipir (DPDP) (Fig. 1) were gifts from Nycomed Imaging/GE Healthcare (Oslo, Norway). Potassium tetrachloroplatinate(II) (K₂PtCl₄), MnCl₂ and ZnCl₂ were purchased from Merck Sweden.

Sample preparations. Prior to the experiments, the chemicals were dissolved in water to suitable strengths. The pH of 1.0 wt% MnDPDP trisodium in water is in the range of 6.36–6.7772. MnDPDP trisodium has a considerable buffering capacity as the pH for 1.0 wt% MnDPDP trisodium solution in 1.0 mM HCl and 1.0 mM NaOH were found to be 6.31–6.32 and 6.37–6.40, respectively. Making use of the high buffering capacity of MnDPDP trisodium, there was no need for using any other buffer, which is of course a great advantage when conducting EPR and optical absorption spectroscopy. Rechecking the samples after conducting the experiments showed pH just below 7.

Physical background. Mn²⁺ has five unpaired electrons in a (3d⁵) configuration, with its electronic ground state in the octahedral ligand field being in the (S) high-spin configuration with an electron spin S = 5/2. It can be described by a spin–Hamiltonian including an electron Zeeman term, a zero field splitting (ZFS) term, a central hyperfine interaction term, the quadrupole interaction term and a nuclear Zeeman term, in the following form:

\[ \mathbf{H} = \mu_B S \mathbf{B} + SDS + SAI + IQI - \frac{Q}{S} \mu_B \mathbf{N} \mathbf{B} \]  

(1)

Here, B is the external magnetic field, S denotes an effective electron spin, I is the nuclear spin and \( \mu_B \) and \( \mu_I \) are the Bohr- and nuclear magneton, respectively. g and \( g_N \) are the electron and nuclear g-tensor, respectively. A is the hyperfine interaction tensor. The ZFS for S > 1/2 is described by the tensor D. The quadrupole interaction for nuclei with I > 1/2 is given by the tensor Q.

In liquid solutions, i.e., hexaqua-Mn²⁺ can be described by just isotropic interactions, since it is subject to fast rotational and tumbling motion, resulting in all anisotropic interactions in the spin–Hamiltonian being averaged out. Therefore, the EPR signal from Mn²⁺ ions in liquid solutions consist of six lines centered at g = 2.0, which are split by isotropic hyperfine interaction with the ⁵⁵Mn nucleus (I = 5/2 with 100% natural abundance). Due to the S = 5/2 electron spin multiplet of Mn²⁺, each of these six hyperfine lines consists of five overlapping electron spin transitions, which occur between adjacent \( M_s = \pm 5/2, \pm 3/2, \pm 1/2 \) sublevels (\( M_s \) is the electron spin projection). Each of these transitions is weighted by its respective transition probability, \( S(\pm 1) - M_s(M_s + 1) \), and, thus, contributes non-equally to the EPR signal intensity. Additionally, incomplete motional averaging of the anisotropic interactions (like fine structure splitting and anisotropic hyperfine interactions) can cause \( M_s \)-dependent broadening. Therefore, the transitions involving higher \( M_s \) states are usually broader than transitions between the inner states \( M_s = \pm 1/2 \). Such a non-equivalent broadening yields additional weighting of the transitions so that broader transitions, i.e. those with higher \( M_s \), have smaller peak-to-peak intensity, as it is observed in this case.

However, ligand-bound Mn²⁺ (like in MnDPDP) is, unlike hexaqua-Mn²⁺, subject to slow tumbling processes, which causes a broadening of the EPR signal, which makes it undetectable in the micromolar concentration range in X-band EPR21. These differences can be used to monitor the Pt²⁺/Mn²⁺ and Zn²⁺/Mn²⁺ exchange by detecting free Mn²⁺ ions.

Competition experiments between MnDPDP and ZnCl₂ or K₂PtCl₄ evaluated by EPR spectroscopy. Pilot experiments indicated that complete Pt²⁺/Mn²⁺ exchange was obtained after 5 days of incubation at room temperature. The long incubation time needed is presumably due to slow Pt²⁺ exchange kinetics19,20 and steric hindrance in the hexa-dendate MnDPDP complex. The steric hindrance of naked DPDP or CaDPDP (where Ca²⁺ is loosely bound to DPDP) is anticipated to be considerably lower. When incubated at 60 °C complete exchange was obtained within 4 h. Anticipating that the reaction rate will double for every 10 °C, 4 h at 60 °C corresponds to about 1 day at 37°C. Competition experiments were conducted between a fixed concentration of 100 μM MnDPDP and 0–1000 μM ZnCl₂ or K₂PtCl₄. All samples, except those of 300 and 1000 μM were incubated 6 h at 60°C; the two highest concentrations were incubated 18 hours in order to make sure that the curves saturated at 100 μM ZnCl₂/K₂PtCl₄.

X-band EPR spectra (9.9 GHz) of Mn²⁺ were recorded on a Bruker Elexsys E500 spectrometer at room temperature making use of Pasteur pipets and the capillary action of their tips, allowing a sample size of 100 μL. Standard measurement parameters were 100 kHz modulation frequency, 10 G modulation amplitude, 12 mW microwave power, and 65 G/s sweep velocity. Signal intensity was determined by double integration after baseline correction, and each EPR session was normalized against the standard curve (Fig. 2).
Optical absorption spectroscopy. Optical absorption spectra in a spectral range from 200–1000 nm were recorded with a Shimadzu UV-2450 spectrometer.

Statistical analyses of competition curves. Competition curves for ZnCl₂ and K₂PtCl₄ were analyzed by fitting the experimental data into the sigmoidal response logistic equation (GraphPad Prism, version 6.0, La Jolla, CA):

\[ [\text{Mn}^{2+}] = \frac{[\text{Mn}^{2+}]_{\text{max}} \cdot [\text{Pt}^{2+}]^q}{[\text{Pt}^{2+}]^q + [\text{Mn}^{2+}]_{\text{max}}^q} \]

by means of non-linear, least squares regression analysis, where [Mn]²⁺, [Mn]²⁺ max, Pt²⁺ denote the observed concentration of free Mn²⁺, maximum concentration of free Mn²⁺, and the concentration of Pt²⁺, respectively. Mn²⁺ₐₙ defines the concentration of Pt²⁺ causing half-maximal increase in free Mn²⁺, and the constant q determines the slope of the curve. The same function was also applied when analyzing the competition curve between MnDPDP and Zn²⁺. From this analysis, the Eₘₐₓ (maximal response) and the pD₂ [−log of the concentrations (M) of a drug causing half maximal responses; EC₅₀] were calculated. Eₘₐₓ (µM) and pD₂ values are presented together with 95% confidence intervals.

Received: 15 July 2019; Accepted: 1 October 2019; Published online: 01 November 2019

References
1. Karlsson, J. O. G., Andersson, R. G. & Jynge, P. Mangafodipir a selective cytoprotectant – with special reference to oxaliplatin and its association to chemotherapy-induced peripheral neuropathy (CIPN). Trans. Oncol. 10, 641–649, https://doi.org/10.1016/j.tranon.2017.04.012 (2017).
2. Karlsson, J. O. G., Ignarro, L. J., Lundstrom, L., Jynge, P. & Almén, T. Calmangafodipir [Ca₄Mn(DPDP)₅], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov. Today 20, 411–421, https://doi.org/10.1016/j.drudis.2014.11.008 (2015).
3. Karlsson, J. O. G., Jynge, P. & Andersson, R. G. Use of non-transition metal coordinated dipyridoxyl compound to prevent and treat chemotherapy-induced PSN. WO 2018/087347 A1, International application published under the Patent Cooperation Treaty (PCT). World International Property Organization, 17 May https://worldwide.espacenet.com/publicationDetails/biblio?ID=WO2018087347&locale=en_EP&FT=DD&date=20180517&CC=WO&NR=WO2018087347&AI=K&CA=A1 (2018).
4. Coriat, R. et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J. Clin. Invest. 124, 262–272, https://doi.org/10.1172/JCI86730 (2014).
5. Glimeilis, B. et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOxe®): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol. 57, 393–402, https://doi.org/10.1080/0284186X.2017.1398836 (2018).
6. Yri, O. E. et al. Mangafodipir as a cytoprotective adjunct to chemotherapy—a case report. Acta Oncol. 48, 633–635, https://doi.org/10.1080/02841860802680427 (2009).
7. Asplund, A., Grant, D. & Karlsson, J. O. Mangafodipir (MnDPDP)- and MnCl₂-induced endothelium-dependent relaxation in bovine mesenteric arteries. J. Pharmacol. Exp. Ther. 271, 609–614, http://ipet.aspetjournals.org/content/271/2/609 (1994).
8. Brouk, H. et al. Manganeese dipyridoxyl diphasphate: MRI contrast agent with antioxidative and cardioprotective properties? Biochem. Biophys. Res. Commun. 254, 768–772, https://doi.org/10.1016/bbrc.1998.01.019 (1999).
9. Bedda, S. et al. Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J. Hepatol. 39, 765–772, https://doi.org/10.1016/S0168-8278(03)00323-8 (2003).
10. Karlsson, J. O. G. et al. Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol. 42, 540–547, https://journals.sagepub.com/doi/10.2884/18101127347340 (2001).
11. Kurt, T. et al. Effects of MnDPDP and ICRF-187 on doxorubicin-induced cardiotoxicity and anticancer activity. Transl. Oncol. 5, 252–259, https://doi.org/10.1016/j.tranon.2012.02.004 (2012).
12. Alexandre, J. et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimetic mangafodipir. J. Natl. Cancer Inst. 98, 236–244, https://doi.org/10.1093/jnci/djj049 (2006).
13. Karlsson, J. O. G. et al. First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy—a translational study. Transl. Oncol. 5, 32–38, https://doi.org/10.1016/j.tranon.2014.11.008 (2012).
14. Karlsson, J. O., Kurt, T., Flechsig, S., Näström, J. & Andersson, R. G. Superior therapeutic index of calmanipipofdin in comparison to mangafodipir as a chemotherapy adjunct. Transl. Oncol. 5, 492–502, https://doi.org/10.1593/jnci/djj12238 (2012).
15. Toft, K. G. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 38, 677–689, 10.1080%2F02841859701972400 (1997).
16. Rocklage, S. M. et al. Structural and Thermodynamic Characterization of Manganese (II) N,N-Dipyridoxylethylenediamine-N, N'-diacetate. A Novel Manganese (II) Chelate. Inorg. Chem. 27, 3530–3534 (1988).
17. Rocklage, S. M., Cacheris, W. P., Quay, S. C., Hahn, F. E. & Raymond, K. N. Manganese(II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 28, 477–485 (1989).
18. Shannon, R. D. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystal. A32, 751–767, https://doi.org/10.1107/S0567739476001551 (1976).
19. Reedijk, J. et al. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. USA 100, 3611–3616, https://doi.org/10.1073/pnas.0737293100 (2003).
20. Pander, P. et al. 1,2,4-Triazines in the synthesis of bipyrinid bisphenoil NOON ligands and their highly luminous tetradentate Pt(II) complexes for solution-processable OLEDs. Inorg. Chem. 57, 3825–3932, https://doi.org/10.1021/acs.inorganichem.7b03175 (2018).
21. Schmidt, P. P., Toft, K. G., Skotland, T. & Andersson, K. Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR. J. Biol. Chem. 7, 241–248, https://doi.org/10.1074/jbc07750100290 (2002).
22. Tirkkonen, B. et al. Physicochemical characterization of mangafodipir trisodium. Acta Radiol. 38, 780–789, https://doi.org/10.1080/02841859701972411 (1997).
23. Butterfield, C. N., Soldatova, A. V., Lee, S. W., Spino, T. G. & Tebo, B. M. Mn(III) oxidation and MnO₂ mineralization by an expressed bacterial multicopper oxidase. Proc. Natl. Acad. Sci. USA 110, 11731–11735, https://doi.org/10.1073/pnas.1303677110 (2013).
24. Zhang, Q. et al. Roles of manganese oxides in degradation of phenol under UV-Vis irradiation: adsorption, oxidation, and photocatalysis. *J. Environ. Sci.* 23, 1904–1910 (2011).
25. Higa, G.M. & Syput, C. Molecular biology and clinical mitigation of cancer treatment-induced neuropathy. *Clinical Medicine Insight: Oncology* 10, 27–34, 10.4137%2FPCMJO.S32810 (2016).
26. McWhinnie, S.R., Goldberg, R.M. & McLeod, H.L. Platinum neurotoxicity pharmacogenetics. *Mol. Cancer Ther.* 8, 10–16, http:// mct.aacrjournals.org/content/8/1/10 (2009).
27. Shord, S. S. et al. Oxalidulin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. *Anticancer Res.* 22, 2301–2309 (2002).
28. Sprovell, J. A. et al. Oxalidulin-induced neurotoxicity is dependent on the organic cation transporter OCT2. *Proc. Natl. Acad. Sci. USA* 110, 11199–12004, https://doi.org/10.1073/pnas.1305321110 (2013).
29. Flora, S. J. S. & Pachauri, V. Chelation in metal intoxication. *Int. J. Environ. Res. Public Health* 7, 2745–2788, https://doi.org/10.3390/ ijerph7072745 (2010).
30. Crisponi, G. & Nurchi, V. M. Chelating agents as therapeutic compounds - basic principles. in *Chelation Therapy in the Treatment of Metal Intoxication* (eds Aaseth, J. et al.) 35–60 (Academic Press, 2016).
31. Andersen, O. Chelation treatment during acute and chronic metal overexposures - experimental and clinical studies in *Chelation Therapy in the Treatment of Metal Intoxication* (eds Aaseth, J. et al.) 86–210 (Academic Press, 2016).
32. Gandara, D. R. et al. Randomized placebo-controlled multicenter evaluation of diethylthiocarbaminate for chemoprotection against cisplatin-induced toxicities. *J. Clin. Oncol.* 13, 490–496 (1995).
33. Graham, M. A. et al. Clinical pharmacokinetics of oxalidulin: a critical review. *Clin. Cancer. Res.* 6, 1205–1218, https://www.ncbi.nlm.nih.gov/pubmed/10778943 (2000).
34. Pearson, G. Hard and Soft Acids and Bases. *J. Am. Chem. Soc.* 85, 3533–3539, https://doi.org/10.1021/ja00905a001 (1963).
35. Howell, S. B., Safai, R., Larson, C. A. & Sailor, M. J. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. *Mol. Pharmacol.* 77, 887–894, [https://doi.org/10.1124/mol.109.063172](https://doi.org/10.1124/mol.109.063172) (2010).
36. Aaseth, J., Gerhardssons, L., Skaug, M. A. & Alexander, J. General chemistry of metal toxicity and basis for metal complexation in *Chelation Therapy in the Treatment of Metal Intoxication* (eds Aaseth, J. et al.) 1–33 (Academic Press, 2016).
37. Marshall, J. L. How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer (editorial). *J. Natl. Cancer Inst.* 100, 107–108, [https://doi.org/10.1093/jnci/djx222](https://doi.org/10.1093/jnci/djx222) (2018).
38. Laurent, A. et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. *Cancer Res.* 65, 948–956, [http://cancerres.aacrjournals.org/content/65/3/948.full-text.pdf](http://cancerres.aacrjournals.org/content/65/3/948.full-text.pdf) (2005).
39. Doroshow, J. H. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity (editorial). *J. Natl. Cancer Inst.* 98, 223–225, [https://doi.org/10.1093/jnci/djx065](https://doi.org/10.1093/jnci/djx065) (2006).
40. Abramag, A. & Bleaney, B. *Electron Paramagnetic Resonance of Transition Ions* (Dover Publications, 1986).
41. Niccolai, N., Tiezzi, E. & Valensin, G. Manganese(II) as magnetic relaxation probe in the study of biomechanisms and of biomacromolecules. *Chem. Rev.* 82, 359–384 (1987).

**Acknowledgements**
This work was supported by grants from Medical Research Council of Southeast Sweden (FORSS–85191) and Karlsson-Tunér Invest AS, Norway. Open access funding provided by Linköping University.

**Author contributions**
J.E.S., I.L. and J.O.G.K. designed the research and performed the experimental work. J.E.S. analyzed the data and J.E.S., I.L. and J.O.G.K. wrote the paper.

**Competing interests**
I.L. and J.O.G. are two of the founders of PledPharma AB and own shares in that company. J.O.G.K. is the main owner of the sponsor Karlsson-Tunér Invest AS. J.O.G.K. is inventor on two granted patent families (e.g., US8377969, US8633174, and US9187509; own by PledPharma AB) and a PCT application (WO 2018/087347 A1; own by Karlsson-Tunér Invest AS), covering the therapeutic use of calmanganafodipir and fodipir. J.E.S. has no competing interest.

**Additional information**
**Correspondence** and requests for materials should be addressed to J.E.S. or J.O.G.K.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2019